Association between immune checkpoint inhibitor antitumor therapy and hepatitis B virus reactivation
10.3969/j.issn.1001-5256.2023.06.027
- VernacularTitle:免疫检查点抑制剂抗肿瘤治疗与HBV再激活的关系
- Author:
Shun CHEN
1
,
2
;
Youcheng XIE
1
;
Junke WANG
1
;
Baoyin ZHAO
1
;
Jiucong ZHANG
1
;
Pan WANG
1
;
Xiaohui YU
1
Author Information
1. Department of Gastroenterology, The 940 Hospital of Joint Logistic Support Force of PLA, Lanzhou 730050, China
2. The Second Hospital of Lanzhou University, Lanzhou 730000, China
- Publication Type:Review
- Keywords:
Liver Neoplasms;
Hepatitis B, Chronic;
Reinfection;
Immune Checkpoint Inhibitors
- From:
Journal of Clinical Hepatology
2023;39(6):1424-1430
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, monotherapy and combination therapy with immune checkpoint inhibitors (ICIs) have achieved good efficacy in a variety of malignancies from solid tumors to lymphomas and have become a standardized and systematic treatment modality for many cancers. However, there is still a lack of studies on the safety of ICIs in hepatitis B virus (HBV)-infected patients with malignancies, and early studies have reported HBV reactivation due to ICI antitumor therapy in clinical practice. With reference to related literature, this article reviews the recent clinical trials and application of ICIs in cancer patients with chronic viral infection and clarifies the efficacy and safety of ICIs in this special population, in order to provide a reference for clinical medication.
